Silver, I highly respect your contributions and opinions and hope you continue. I would have responded sooner, but I was a little covered up.
The attached is a stock commentary from Catherine Wood of ARK Investment Management, as of August 9,2019.
Organovo Holdings (ONVO)
Organovo Holdings (ONVO) traded down 26.5% on Wednesday as it ended its lead program for therapeutic 3D printed liver tissue given development timeline concerns. We still have full conviction in the company’s 3D printing platform for biological tissues. Organovo has decided on a new focus that should deliver shareholder value within a shorter timeframe.
We are especially encouraged by its four-year collaborations with Murdoch Children’s Research Institute (MCRI) under professor Melissa Little, and the Leiden University Medical Center. These partners are two of the top stem cell research institutes in the world. Together with Organovo, they are developing stem-cell based bio-printed tissue treatments for kidney disease, highlighting the value in Organovo’s platform.
Now selling at less than its cash, ONVO has become a call option on an important stem cell research platform. We believe that stem cell research will help decipher the code of life, and that therapies derived from bio-printed stem cell technologies will offer cures for chronic diseases, starting with those related to the kidney.